Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods -Fairmont Medical Products Pty Ltd, Genera Biosystems Ltd, The Australian Red Cross Blood Service, Integria Healthcare Australia Pty Ltd, The Australian Red Cross Blood Service, Sunnyfield, Sea Dragon Botanicals Pty Ltd, The Australian Red Cross Blood Service, Abbvie Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, safety and efficacy of therapeutic goods available in Australia. It was introduced to address the need for a comprehensive legislative framework to ensure that therapeutic goods meet acceptable standards. The Act is administered by the Therapeutic Goods Administration (TGA) under the auspices of the Commonwealth of Australia’s Department of Health. The primary policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia are of an acceptable quality, safe, and effective. The Act provides the legal foundation for the regulation of therapeutic goods, including medicines, medical devices, blood and blood components, and tissues. This legislation allows the TGA to control the importation, manufacture, supply and advertising of therapeutic goods, thereby safeguarding the health and wellbeing of the Australian public.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods within Australia, including the licensing of manufacturers. The Act encompasses entities engaged in the manufacture of therapeutic goods, which are products intended to diagnose, treat, prevent, or alleviate a disease, disorder, or abnormal physical state. The Act extends its reach to all manufacturers within the Commonwealth of Australia, ensuring that the production of therapeutic goods adheres to stringent quality and safety standards. The revocation of a licence under the Act is a significant action that can be initiated by the Secretary of the Department of Health, either at the request of the manufacturer or upon finding non-compliance. This revocation terminates the manufacturer's authority to produce therapeutic goods, impacting their ability to distribute these products within Australia. The Act provides for the revocation process to be detailed in subordinate instruments, which may further specify the conditions and procedures for such actions.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides for the regulation of therapeutic goods in Australia, including the manufacture of these goods. Under Section 41(1)(d), the Secretary can revoke a licence to manufacture therapeutic goods, which is precisely what has been done in this Gazette. Specifically, Licence No. MI-22102004-LI-000041-1 held by Fairmont Medical Products Pty Ltd, Licence No. MI-2009-LI-01450-3 held by Genera Biosystems Ltd, Licence No. MI-17082005-LI-000791-1 held by The Australian Red Cross Blood Service, Licence No. MI-2010-LI-01252-3 held by Integria Healthcare Australia Pty Ltd, Licence No. MI-16082005-LI-000783-1 held by The Australian Red Cross Blood Service, Licence No. MI-2009-LI-02745-3 held by Sunnyfield, Licence No. MI-05112004-LI-000125-1 held by Sea Dragon Botanicals Pty Ltd, Licence No. MI-24082005-LI-000852-1 held by The Australian Red Cross Blood Service, and Licence No. MI-04112004-LI-000114-1 held by Abbvie Pty Ltd have all been revoked. These revocations were made at the request of the respective manufacturers. The revocation of these licences imposes obligations on the affected entities. Firstly, they must cease all manufacturing activities related to therapeutic goods immediately upon the revocation. Secondly, they must comply with any additional requirements or conditions set out by the Therapeutic Goods Administration (TGA) as part of the revocation process. This might include the return of any therapeutic goods that are currently in their possession or the submission of any relevant documentation to the TGA. Finally, the entities must ensure that they do not engage in any manufacturing activities without a valid licence, as this would be unlawful. Failure to comply with the obligations imposed by the revocation can lead to various consequences. For the manufacturers, non-compliance can result in civil or criminal penalties. Under the Act, an individual or entity can be subject to fines and/or imprisonment for manufacturing therapeutic goods without a valid licence. The specific penalties depend on the severity of the breach and can be significant, with maximum penalties including fines of up to $1,215,000 for corporations and imprisonment for up to 10 years for individuals. Additionally, ongoing non-compliance can lead to further enforcement actions by the TGA, including court proceedings and additional fines or penalties. It is crucial for the affected entities to take the revocation seriously and to ensure full compliance to avoid these severe consequences.